Momordica charantia extracts ameliorate insulin resistance by regulating the expression of socs-3 and jnk in type 2 diabetes mellitus rats

Pharmaceutical Biology

Volumn 55, Issue 1, 2017, Pages 2170-2177

  Ma, Chunyu ^a   Yu, Hongyu ^a   Xiao, Ying ^a   Wang, Huijiao ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

C Jun N terminal kinase; IL 6; Liver glycogen; Suppressor of cytokine signaling 3; TNF a

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN; INSULIN; INTERLEUKIN 6; MESSENGER RNA; METFORMIN; MOMORDICA CHARANTIA EXTRACT; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR; ANTIDIABETIC AGENT; PLANT EXTRACT; SOCS3 PROTEIN, RAT; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCOGEN MUSCLE LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT; TIME TO TREATMENT; WESTERN BLOTTING; ANIMAL; BLOOD; CHEMISTRY; DOSE RESPONSE; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; LIPID DIET; MOMORDICA CHARANTIA;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MOMORDICA CHARANTIA; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STREPTOZOCIN; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN;

EID: 85049409746     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.1080/13880209.2017.1396350     Document Type: Article

References (33)

1. Adeghate E, Schattner P, Dunn E. 2006. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 1084:1–29.
2. Chao CY, Sung PJ, Wang WH, Kuo YH. 2014. Anti-inflammatory effect of Momordica charantia in sepsis mice. Molecules. 19:12777–12788.
3. Chaturvedi P, George S, Milinganyo M, Tripathi YB. 2004. Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats. Phytother Res. 18:954–956.
4. Chen Q, Chan LL, Li ET. 2003. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizers glucose tolerance in rats fed a high fat diet. J Nutr. 133:1088–1093.
5. Choi JJ, Park MY, Lee HJ, Yoon DY, Lim Y, Hyun JW, Zouboulis CC, Jin M. 2012. TNF-a increases lipogenesis via JNK and PI3K/Akt pathways in SZ95 human sebocytes. J Dermatol Sci. 65:179–188.
6. Chun CS, Cheng HL, Wei LL, Wu JB. 2009. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J Ethnopharmacol. 123:82–90.
7. Chun CS, Min TS, Cheng HL, Jin BW. 2014. Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice. Phytother Res. 28:363–371.
8. Donath MY, Shoelson SE. 2011. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 11:98–107.
9. Efird JT, Choi YM, Davies SW, Mehra S, Anderson EJ, Katunga LA. 2014. Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes. Int J Environ Res Public Health. 11:2328–2345.
10. Fujino H, Itoda S, Sako S, Matsuo K, Sakamoto E, Yokoyama T. 2013. Reliability of HOMA-IR for evaluation of insulin resistance during peri-operative period. Masui. 62:140–146.
11. Galic S, Sachithanandan N, Kay TW, Steinberg GR. 2014. Suppressor of cytokine signalling (SOCS) proteins as guardians of inflammatory responses critical for regulating insulin sensitivity. Biochem J. 461:177–188.
12. Habicht SD, Ludwig C, Yang RY, Krawinkel MB. 2014. Momordica charantia and type 2 diabetes: from in vitro to human studies. Curr Diabetes Rev. 10:48–60.
13. Hashimoto R, Sakai K, Matsumoto H, Iwashita M. 2010. Tumor necrosis factor-alpha (TNF-alpha) inhibits insulin-like growth factor-I (IGF-I) activities in human trophoblast cell cultures through IGF-I/insulin hybrid receptors. Endocr J. 57:193–200.
14. Hazarika R, Parida P, Neog B, Yadav RNS. 2012. Binding Energy calculation of GSK-3 protein of Human against some anti-diabetic compounds of Momordica charantia linn (Bitter melon). Bioinformation. 8:251–254.
15. Kalupahana NS, Moustaid MN, Claycombe KJ. 2012. Immunity as a link between obesity and insulin resistance. Mol Aspects Med. 33:26–34.
16. Koren S, Fantus G. 2007. Inhibition of the protein tyrosine phosphatase PTP-1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 21:621–640.
17. Kumar R, Balaji S, Uma TS, Sehgal PK. 2009. Fruit extracts of Momordica charantia potentiate glucose uptake and up-regulate Glut-4, PPAR gamma and PI3K. J Ethnopharmacol. 126:533–537.
18. Kwon H, Pessin JE. 2013. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne). 4:71.
19. Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S. 2009. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Br J Nutr. 102:1703–1708.
20. Lee BC, Lee J. 2014. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 1842:446–462.
21. Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR, Suzuki I. 2001. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol. 47:340–344.
22. 2þ. Am J Physiol Endocrinol Metab. 282:1008–1013.
23. Roach PJ, Depaoli RA, Hurley TD, Tagliabracci VS. 2012. Glycogen and its metabolism: some new developments and old themes. Biochem J. 441:763–787.
24. Sharfi H, Eldar-Finkelman H. 2008. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-ter-minal kinase plays a role in hepatic insulin signaling. Am J Physiol Endocrinol Metab. 294:307–315.
25. Sharma BR, Kim HJ, Rhyu DY. 2015. Caulerpa lentillifera extract ameliorates insulin resistance and regulates glucose metabolism in C57BL/KsJ-db/db mice via PI3K/AKT signaling pathway in myocytes. J Transl Med. 13:62.
26. Shi H, Tzameli I, Bjorbaek C, Flier JS. 2004. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem. 279:34733–34740.
27. Soo JY, Jung MC, Se EP, Eun JR, Won YL, Ki WO, Sung WP, Cheol YP. 2015. Preventive effects of bitter melon (Momordica charantia) against insulin resistance and diabetes are associated with the inhibition of NF-jB and JNK pathways in high-fat-fed OLETF rats. J Nutr Biochem. 26:234–240.
28. Spasov AA, Samokhina MP, Kheyfets IA, Dugina JL, Martyushev Poklad AV, Sergeeva SA, Epstein OI. 2007. Study of antidiabetic activity of a new ultralow-dose antibody preparation on the model of streptozotocin diabetes in rats. Bull Exp Biol Med. 144:46–48.
29. Tsuchiya A, Kanno T, Nishizaki T. 2014. PI3 kinase directly phosphorylates Akt1/2 at Ser473/474 in the insulin signal transduction pathway. J Endocrinol. 220:49–59.
30. Yoshihiro I, Ryoichi B, Shigeru H, Ozawa Y, Arima H, Oiso Y. 2012. TNFa increases hypothalamic PTP-1B activity via the NF jB pathway in rat hypothalamic organotypic cultures. Regul Pept. 174:58–64.
31. White MF. 2002. Irs proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 3:413–422.
32. Wormald S, Hilton DJ. 2004. Inhibitors of cytokine signal transduction. J Biol Chem. 279:821–824.
33. Yin J, Zhang H, Ye J. 2008. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 8:99–111.